Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
NCT ID: NCT04644432
Last Updated: 2020-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
30 participants
INTERVENTIONAL
2020-03-06
2022-09-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The patients are assigned into 4 treatment arms according to the results of their DNA and RNA analyses. All patients receive electronic questionnaires regarding symptoms and side effects weekly and questionnaires regarding quality of life monthly. Based on each patient's answers of the questionnaires the patient receives advices in the app to reduce the symptoms and side effects or the patient is instructed to contact the hospital.
The hypothesis: Basing the choice of first-line treatment for DNA mutations and RNA profiles in a heterogeneous patient population increases the overall response rate for the total population to 30% compared to 10% for historical cohorts.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A - for patients with a DNA mutation that match a targeted treatment
Listed below are the possible study drugs and dosages:
Erlotinib 150 mg once a day for 4 weeks.
Osimertinib 80 mg once a day for 4 weeks.
Alectinib 600 mg twice a day for 4 weeks
Dabrafenib 150 mg twice a day combined with Trametinib 2 mg once a day for 4 weeks
Trastuzumab-emtansin iv infusion 3.6 mg/kg every 3rd week
Olaparib 400 mg twice a day for 4 weeks
Pembrolizumab iv infusion 2 mg/kg every 3rd week
Cabozantinib 60 mg once a day for 4 weeks
Crizotinib 250 mg twice a day for 4 weeks
Palbociclib 125 mg once a day in3 weeks, hereafter pause for one week
Imatinib 400 mg once a day for 4 weeks
If the patient can fit in several arms, arm A or the arm closest to arm A is chosen.
Medication (A specification is listed under each arm)
Study drugs and dosages are listed in the description of arms.
Patient reported outcomes measurement
PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.
The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.
For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish.
B - for patients with an angiogen profile
Study drug: Sunitinib peroral tablet 50 mg once a day for 4 weeks, hereafter pause for 2 weeks (4/2 schedule or 2/1 schedule).
If the patient can fit in several arms, arm A or the arm closest to arm A is chosen.
Medication (A specification is listed under each arm)
Study drugs and dosages are listed in the description of arms.
Patient reported outcomes measurement
PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.
The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.
For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish.
C - for patients with an immune profile
Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week.
If the patient can fit in several arms, arm A or the arm closest to arm A is chosen.
Medication (A specification is listed under each arm)
Study drugs and dosages are listed in the description of arms.
Patient reported outcomes measurement
PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.
The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.
For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish.
D - for patients that have neither mutations nor an immune- or angiogen profile
Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week.
If the patient can fit in several arms, arm A or the arm closest to arm A is chosen.
Medication (A specification is listed under each arm)
Study drugs and dosages are listed in the description of arms.
Patient reported outcomes measurement
PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.
The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.
For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Medication (A specification is listed under each arm)
Study drugs and dosages are listed in the description of arms.
Patient reported outcomes measurement
PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.
The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.
For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The patient must be willing and able to follow the protocol.
3. Age ≥ 18 years
4. Histological biopsy-confirmed inoperable, locally advanced or metastatic non-cc RCC or 100% sarcomatoid tumour arising from the kidney found unsuited for surgery with a curative intent. Nephrectomy is not mandatory.
1. If the primary disease was diagnosed more than 1 year ago, a fresh medium needle biopsy must be collected to confirm the diagnosis and tissue must be collected for DNA and RNA analyses.
2. If a patient with inoperable relapse had a nephrectomy less than 1 year ago, and no tissue samples are stored in Dansk CancerBiobank, a fresh medium needle biopsy must be collected for DNA and RNA analyses.
3. In cases where metastatic disease was confirmed by biopsy more than 1 year ago without initiated treatment, the patient is offered a fresh medium needle biopsy, but this is not mandatory for inclusion.
4. If the patient had a nephrectomy using tissue from Dansk CancerBiobank and has been diagnosed with metastases within 1 year, the patient must be offered a fresh medium needle biopsy from a metastasis if the metastasis is easily accessible for biopsy, but a fresh biopsy is not mandatory for inclusion.
5. A medium needle biopsy is mainly taken from a metastasis, but biopsy from a renal tumour is allowed.
6. A biopsy may not be taken from bones as it cannot be used for molecular analysis.
7. If the primary tumour is a proven clear cell RCC, but the biopsy from a metastasis shows non-cc RCC, the patient can be included in the study.
5. Sufficient tissue for DNA analyses, corresponding to 10 slides and RNA analyses corresponding to 1000 tumour cells.
6. Females with a negative pregnancy test or of non-childbearing potential (menopausal, hysterectomy or ovariectomy) and non-breastfeeding.
7. Females of childbearing potential (\<2 years after last menstrual period) and males must use effective contraception (pills, intrauterine device, diaphragm or condom with spermicide or sterilisation).
8. Measurable disease (according to RECIST 1.1 criteria)
9. Karnofsky Performance status ≥ 70% / ECOG Performance status 0-2.
10. Life expectancy more than 3 months.
11. At baseline, the laboratory values must be: Haematology: Leukocytes ≥ 3.0 x 109/l, thrombocytes ≥ 100 x 109/l, haemoglobin ≥ 6.2 mmol/l.
12. Biochemistry: International Normalized Ratio (INR) ≤ 1.5, APTT ≤ 1.5 x upper limit of normal (ULN) Total bilirubin ≤ 1.5 x ULN, aspartate transaminase, alanine aminotransferase ≤ 2.5 x ULN for patients without liver metastases, ≤ 5 x ULN for patients with liver metastases. Estimated glomerular filtration rate (eGFR) \> 30.
Exclusion Criteria
2. Former adjuvant treatment with immune checkpoint inhibitors.
3. Major surgical procedure, open surgical biopsy or significant trauma within 28 days prior to initiation.
4. Serious non-healing wound, ulcer or bone fracture.
5. Auto-immune disease or other condition requiring systemic treatment with either corticosteroids (prednisolone \> 10 mg/day or similar) or other immunosuppressive drugs
6. Metastases in the central nervous system (CNS). The patient must have an MRI scan (preferred) or CT scan of the brain (using contrast agent if possible) within 28 prior to initiation.
7. Seizures which cannot be managed with standard medical treatment.
8. If urine dipstick with protein ≥ 3+, urine must be collected over a period of 24 hours which must be \< 3.5 grams/day. If degree 2 proteinuria, urine must be collected over a period of 24 hours prior to each prescription.
9. Other malignancy within 5 years (except for curatively treated basal cell carcinoma of the skin and/or cervix carcinoma in situ).
10. Uncontrolled hypertension (≥ 150 mm Hg systolic and/or ≥ 100 mm Hg diastolic) despite maximum antihypertensive medical treatment.
11. Clinically significant (i.e. active) cardiovascular disease, such as cerebrovascular conditions (≤ 6 months), myocardial infarction (≤ 6 months), unstable angina, New York Heart Association (NYHA) congestive heart failure ≥ degree III or serious cardiac arrhythmia requiring medical treatment. Patients with well-managed Atrial fibrillation/ atrial flutter may be included.
12. Treatment using other investigational drugs or participation in other studies.
13. Previous or current other diseases, metabolic dysfunction, clinical findings on physical examination or clinical laboratory findings that give suspicion of a disease or condition that would contraindicate the use of an investigational drug or a patient with a high risk of treatment complications.
14. Patients where the investigator finds that patient compliance prevents safe completion of the treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Herlev and Gentofte Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ida Rasmussen
Principal investigator, MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ida Marie L Rasmussen, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Oncology, Herlev and Gentofte Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Oncology, Herlev and Gentofte Hospital
Herlev, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anne Kirstine H Moeller, MD, PhD
Role: primary
Jesper A Palshof, MD, PhD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Rasmussen IML, Soerensen AV, Moller AK, Persson GF, Palshof JA, Taarnhoj GA, Pappot H. Individualizing the Oncological Treatment of Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma by Using Gene Sequencing and Patient-Reported Outcomes: Protocol for the INDIGO Study. JMIR Res Protoc. 2022 Sep 15;11(9):e36632. doi: 10.2196/36632.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-001316-38
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
PACTIUS
Identifier Type: OTHER
Identifier Source: secondary_id
GCP
Identifier Type: OTHER
Identifier Source: secondary_id
UR1909
Identifier Type: -
Identifier Source: org_study_id